Quadrivalent influenza vaccine in the United States

References

• Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25:5086 - 96; http://dx.doi.org/10.1016/j.vaccine.2007.03.046; PMID: 17544181
   PubMed Web of Science ®Google Scholar
• Fairbrother G, Cassedy A, Ortega-Sanchez IR, Szilagyi PG, Edwards KM, Molinari NA, Donauer S, Henderson D, Ambrose S, Kent D, et al, New Vaccine Surveillance Network (NVSN). High costs of influenza: Direct medical costs of influenza disease in young children. Vaccine 2010; 28:4913 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.05.036; PMID: 20576536
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. MMWR Recomm Rep 2013; 62:RR-07 1 - 43; PMID: 24048214
   PubMedGoogle Scholar
• Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990; 175:59 - 68; http://dx.doi.org/10.1016/0042-6822(90)90186-U; PMID: 2309452
   PubMed Web of Science ®Google Scholar
• Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus. J Mol Evol 2008; 66:655 - 63; http://dx.doi.org/10.1007/s00239-008-9119-z; PMID: 18504518
   PubMed Web of Science ®Google Scholar
• Paul Glezen W, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. The burden of influenza B: a structured literature review. Am J Public Health 2013; 103:e43 - 51; http://dx.doi.org/10.2105/AJPH.2012.301137; PMID: 23327249
   PubMed Web of Science ®Google Scholar
• Chen JM, Guo YJ, Wu KY, Guo JF, Wang M, Dong J, Zhang Y, Li Z, Shu YL. Exploration of the emergence of the Victoria lineage of influenza B virus. Arch Virol 2007; 152:415 - 22; http://dx.doi.org/10.1007/s00705-006-0852-6; PMID: 17075722
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012; 8:81 - 8; http://dx.doi.org/10.4161/hv.8.1.17623; PMID: 22252006
   PubMed Web of Science ®Google Scholar
• Treanor J. Influenza vaccine--outmaneuvering antigenic shift and drift. N Engl J Med 2004; 350:218 - 20; http://dx.doi.org/10.1056/NEJMp038238; PMID: 14724300
   PubMed Web of Science ®Google Scholar
• Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013; 208:544 - 53; http://dx.doi.org/10.1093/infdis/jit263; PMID: 23847058
   PubMed Web of Science ®Google Scholar
• Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010; 28:2149 - 56; http://dx.doi.org/10.1016/j.vaccine.2009.11.068; PMID: 20003926
   PubMed Web of Science ®Google Scholar
• Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. Expert Rev Vaccines 2012; 11:1293 - 303; http://dx.doi.org/10.1586/erv.12.108; PMID: 23151111
   PubMed Web of Science ®Google Scholar
• Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993 - 8; http://dx.doi.org/10.1016/j.vaccine.2011.12.098; PMID: 22226861
   PubMed Web of Science ®Google Scholar
• Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011; 29:9391 - 7; http://dx.doi.org/10.1016/j.vaccine.2011.09.109; PMID: 21983154
   PubMed Web of Science ®Google Scholar
• Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012; 31:745 - 51; http://dx.doi.org/10.1097/INF.0b013e31825687b0; PMID: 22466322
   PubMed Web of Science ®Google Scholar
• Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >=18 years. BMC Infect Dis 2013; 13:343; http://dx.doi.org/10.1186/1471-2334-13-343; PMID: 23883186
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207:1878 - 87; http://dx.doi.org/10.1093/infdis/jit091; PMID: 23470848
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013; 31:770 - 6; http://dx.doi.org/10.1016/j.vaccine.2012.11.074; PMID: 23228813
   PubMed Web of Science ®Google Scholar